[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100387552":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":52,"collaborators":18,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":18,"enrollmentInfo":64,"targetDuration":18,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":18,"overallStatus":33,"whyStopped":18,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nice","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Cohort","All patients included will have to be taken blood samples",[12],"Other: Blood sample",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Blood sample","Serum samples will be sent for centralised analyses in Nice.\n\nOn these samples, different analysis will be performed :\n\n* anti-PLA2R1 and anti-THSD7A antibodies\n* anti-PLA2R1 and anti-THSD7A epitopes\n* HLA typing",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Barbara Seitz-polski","Hopital de l'Archet laboratoire immunology, 151 route de sain-Antoine de Ginestière 06200 Nice","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Barbara SEITZ-POLSKI, MD","CONTACT","+33 4 92 03 55 02","seitz-polski.b@chu-nice.fr",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"CHU de Nice, Hôpital de l'Archet","RECRUITING","Nice","Alpes Maritime","06200","France","FR",{"type":40,"coordinates":41},"Point",[42,43],7.26608,43.70313,{"lat":43,"lon":42},[46,49,51],{"name":47,"role":27,"phone":48,"phoneExt":18,"email":29},"Barbara Seitz-Polski","+33492035502",{"name":50,"role":27,"phone":18,"phoneExt":18,"email":18},"Barbara SEITZ-POLSKI, PhD",{"name":47,"role":23,"phone":18,"phoneExt":18,"email":18},{"type":53,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100387552","immunopathological-analysis-in-a-french-national-cohort-of-membranous-nephropathy-100387552",false,"NCT04326218","Immunopathological Analysis in a French National Cohort of Membranous Nephropathy","Immunopathological Analysis in a French National Cohort of Membranous Nephropathy (IHMN)","IHMN","Inclusion Criteria:\n\n* Age 18 years or more\n* Biopsy on a native kidney consistent with MN and\u002For positivity for serum anti-PLA2R1 and\u002For anti-THSD7A antibodies\n* Signed informed consent\n\nExclusion Criteria:\n\n* Diagnosis error based on the kidney biopsy staining or on serology analyses for the positivity for anti-PLA2R1 and\u002For anti-THSD7A\n* Patients unable to give an informed consent\n* Patients withdrawing an informed consent","ALL","18 Years",{"count":65,"type":66},400,"ESTIMATED","INTERVENTIONAL",[69],"NA","National cohort of all cases of membranous nephropathy (MN) during a 1 year period in France, based on a pathological and\u002For serological diagnostic, collecting the data on:\n\n* incidence of MN\n* prevalence of anti-PLA2R1 and anti-THSD7A\n* clinical outcome one year after diagnosis or after relapse (complete remission, partial remission or persistent nephrotic syndrome)\n* environmental risk factors for the onset of MN\n* HLA markers\n* patient care status in France",[72],"Membranous Nephropathy","2026-06-15",{"date":75,"type":76},"2026-06-16","ACTUAL",{"date":78,"type":76},"2020-07-04",{"date":80,"type":66},"2031-12-03",{"name":5,"class":6},1]